Krogerus advises Bioretec on its rights offering

Krogerus advised Bioretec on its oversubscribed rights offering of EUR 9.2 million. The rights offering was carried out as the first in Finland under the new exemption document regime under the EU Prospectus Regulation. Danske Bank and DNB Carnegie Investment Bank acted as Joint Global Coordinators in the rights offering.

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of bioresorbable orthopedic implants. The company has unique expertise combining materials engineering and biochemistry in active implants that promote bone growth and accelerate fracture healing after orthopedic surgery. Bioretec's shares are listed on Nasdaq First North Growth Market Finland.

The Krogerus team was led by Partner Tom Fagernäs and Counsel Samuli Torpisto. They were primarily assisted by Senior Associate Olli Silvennoinen and Associates Manu Honkanen, Eemeli Kastikainen, Marika Nieminen and Jonna Vähäsöyrinki (all Capital Markets and Public M&A).